Mary Ann Liebert: Controversy Swirls Around Adipose-Derived Cell Therapies for Reparative Medicine
February 20, 2020
February 20, 2020
NEW ROCHELLE, New York, Feb. 20 -- Mary Ann Liebert Inc. issued the following news release:
Challenging the U.S. Food and Drug Administration's current approach to evaluating and approving adipose-based cell therapies used in reparative medicine, a group of researchers proposes a new path forward that focuses on patient safety and includes evidence-based medical practice. Details of this new path forward and a response from the FDA are both published in Stem Cells and Development, a . . .
Challenging the U.S. Food and Drug Administration's current approach to evaluating and approving adipose-based cell therapies used in reparative medicine, a group of researchers proposes a new path forward that focuses on patient safety and includes evidence-based medical practice. Details of this new path forward and a response from the FDA are both published in Stem Cells and Development, a . . .